BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32747469)

  • 1. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.
    Borch TH; Andersen R; Ellebaek E; Met Ö; Donia M; Svane IM
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32747469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
    Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
    Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
    Hall MS; Mullinax JE; Cox CA; Hall AM; Beatty MS; Blauvelt J; Innamarato P; Nagle L; Branthoover H; Wiener D; Schachner B; Martinez AJ; Richards AD; Rich CJ; Colón Colón M; Schell MJ; Teer JK; Khushalani NI; Weber JS; Mulé JJ; Sondak VK; Pilon-Thomas S; Sarnaik AA
    Clin Cancer Res; 2022 Dec; 28(24):5317-5329. PubMed ID: 36215121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.
    Lövgren T; Wolodarski M; Wickström S; Edbäck U; Wallin M; Martell E; Markland K; Blomberg P; Nyström M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
    Oncoimmunology; 2020 Jul; 9(1):1792058. PubMed ID: 32923156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
    Rohaan MW; Borch TH; van den Berg JH; Met Ö; Kessels R; Geukes Foppen MH; Stoltenborg Granhøj J; Nuijen B; Nijenhuis C; Jedema I; van Zon M; Scheij S; Beijnen JH; Hansen M; Voermans C; Noringriis IM; Monberg TJ; Holmstroem RB; Wever LDV; van Dijk M; Grijpink-Ongering LG; Valkenet LHM; Torres Acosta A; Karger M; Borgers JSW; Ten Ham RMT; Retèl VP; van Harten WH; Lalezari F; van Tinteren H; van der Veldt AAM; Hospers GAP; Stevense-den Boer MAM; Suijkerbuijk KPM; Aarts MJB; Piersma D; van den Eertwegh AJM; de Groot JB; Vreugdenhil G; Kapiteijn E; Boers-Sonderen MJ; Fiets WE; van den Berkmortel FWPJ; Ellebaek E; Hölmich LR; van Akkooi ACJ; van Houdt WJ; Wouters MWJM; van Thienen JV; Blank CU; Meerveld-Eggink A; Klobuch S; Wilgenhof S; Schumacher TN; Donia M; Svane IM; Haanen JBAG
    N Engl J Med; 2022 Dec; 387(23):2113-2125. PubMed ID: 36477031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cells Expanded from PD-1
    Li T; Zhao L; Yang Y; Wang Y; Zhang Y; Guo J; Chen G; Qin P; Xu B; Ma B; Zhang F; Shang Y; Li Q; Zhang K; Yuan D; Feng C; Ma Y; Liu Z; Tian Z; Li H; Wang S; Gao Q
    Cancer Res; 2021 Apr; 81(8):2184-2194. PubMed ID: 33408117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.
    Borch TH; Harbst K; Rana AH; Andersen R; Martinenaite E; Kongsted P; Pedersen M; Nielsen M; Kjeldsen JW; Kverneland AH; Lauss M; Hölmich LR; Hendel H; Met Ö; Jönsson G; Donia M; Svane IM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34210820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
    Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
    Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Hulen TM; Friese C; Kristensen NP; Granhøj JS; Borch TH; Peeters MJW; Donia M; Andersen MH; Hadrup SR; Svane IM; Met Ö
    Front Immunol; 2023; 14():1180997. PubMed ID: 37359554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
    Zikich D; Schachter J; Besser MJ
    Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
    Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
    Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
    Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
    Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
    Plesca I; Tunger A; Müller L; Wehner R; Lai X; Grimm MO; Rutella S; Bachmann M; Schmitz M
    Front Immunol; 2020; 11():364. PubMed ID: 32194568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
    Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
    Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
    Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
    J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.